3 Stocks That Soared Stupendously This Week   4-25-14
Upcoming SlideShare
Loading in...5

Like this? Share it with your network


3 Stocks That Soared Stupendously This Week 4-25-14



These 3 health-care stocks knocked the ball out of the park this week.

These 3 health-care stocks knocked the ball out of the park this week.



Total Views
Views on SlideShare
Embed Views



16 Embeds 7,412

http://www.fool.com 7309
http://m.fool.com 54
http://www.barchart.com 15
http://barchartjson.websol.barchart.com 8
http://translate.googleusercontent.com 7
http://www.dailyfinance.com 7
http://cms.fool.com 3
http://www.mysanantonio.com 1
http://www.beaumontenterprise.com 1
http://www.greenwichtime.com 1
http://www.seattlepi.com 1 1
http://m.sfgate.com 1 1
http://quotes.barchart.com 1
http://www.google.com 1



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

3 Stocks That Soared Stupendously This Week 4-25-14 Presentation Transcript

  • 1. 3 Stocks That Soared Stupendously This Week
  • 2. Biotech and health-care certainly aren’t as hot as they were just a few months ago. There are still several bright spots in the sectors, though. Here are three health-care stocks racking up gains of 27% or more over the last few days.
  • 3. Shares of the biotech skyrocketed 50% this week. Sarepta Therapeutics (Nasdaq:SRPT) Source: Yahoo! Finance
  • 4. • Sarepta announced plans to submit a New Drug Application, or NDA, for eteplirsen by the end of 2014 • Its Duchenne muscular dystrophy drug can proceed on an Accelerated Approval pathway • The company must supply additional data to support eteplirsen’s efficacy and safety with the NDA • This news marked a major reversal by the FDA, which had previously called an NDA for the drug as “premature” with “considerable doubt” about some aspects of Sarepta’s clinical studies Why Sarepta shares skyrocketed
  • 5. Shares of the medical marijuana company jumped nearly 35% higher for the week. GW Pharmaceuticals (Nasdaq:GWPH) Source: Yahoo! Finance
  • 6. • GW Pharmaceuticals benefited from two endorsements • Investment firm Morgan Stanley initiated coverage with an “overweight” rating • CNBC’s Jim Cramer also plugged GW’s prospects on his television program • GW’s cannabinoid multiple sclerosis drug Sativex is approved in 24 countries • Epilepsy drug Epidiolex holds promise for driving future growth Why GW hit the jackpot
  • 7. Shares of the biopharmaceutical firm vaulted 27% higher this week. Galena Biopharma (Nasdaq:GALE) Source: Yahoo! Finance
  • 8. • Anticipation appears to be the impetus for Galena’s big gains -- the company announces Q1 results on May 6 • Investors will focus on sales for breakthrough cancer pain drug Abstral and any news about cancer drug Neuvax • Neuvax could become a big winner for Galena should the phase 3 study currently underway produce solid results • It remains to be seen if this week’s jump marks a comeback for Galena following news announced last month that the SEC is investigating some stock promotion activities conducted by the company Why Galena galloped
  • 9. • Successful clinical results for GW Pharmaceuticals’ Epidiolex and Galena’s Neuvax could power both stocks to higher levels • Sarepta’s stock price remains well below levels from last October, when investors thought the company would receive a green light from the FDA to move forward with the NDA for eteplirsen • Volatility could still reign for Sarepta – and there’s a good chance that the FDA will still not approve eteplirsen this go-around • Over the long run, though, my view is that Sarepta will be able to make a solid case for eteplirsen and the stock will emerge (again) as a big winner Best pick to keep soaring?
  • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!